{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"NeuroOne\u00ae Issues Letter to Shareholders - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"5D2suXl8cx\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-issues-letter-to-shareholders\/\">NeuroOne\u00ae Issues Letter to Shareholders<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/neuroone-issues-letter-to-shareholders\/embed\/#?secret=5D2suXl8cx\" width=\"600\" height=\"338\" title=\"&#8220;NeuroOne\u00ae Issues Letter to Shareholders&#8221; &#8212; Market Newsdesk\" data-secret=\"5D2suXl8cx\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Company Now Fully Funded Through at least Fiscal 2026; Company Confirms No Material Impact from Global Tariffs EDEN PRAIRIE, Minn., April 16, 2025 (GLOBE NEWSWIRE) &#8212; NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (&#8220;NeuroOne&#8221; or the &#8220;Company&#8221;), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, has issued a letter to shareholders from CEO, Dave Rosa. Dear Shareholders, In recent months, NeuroOne has achieved several significant milestones, including the expansion of our commercial partnership with Zimmer Biomet, progress towards the submission of a 510(k) filing to treat facial pain, and continued product development momentum in areas of back pain management and drug delivery. Most notably, the expansion of our partnership with Zimmer &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMzExOCM2ODY4Nzg4IzUwMDExNDgzNA=="}